Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022004620 - METHOD FOR MANUFACTURING COMPOSITION INCLUDING ANTIGEN-SPECIFIC ANTIBODY-PRODUCING CELLS, METHOD FOR MANUFACTURING VACCINE COMPOSITION, CELL SEPARATION KIT, AND VACCINE COMPOSITION

Publication Number WO/2022/004620
Publication Date 06.01.2022
International Application No. PCT/JP2021/024262
International Filing Date 27.06.2021
IPC
C12N 5/0781 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0781B cells; Progenitors thereof
A61K 35/17 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 31/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 31/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
10Antimycotics
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Applicants
  • 株式会社NPT NPT CO., LTD. [JP]/[JP]
Inventors
  • 原 健一郎 HARA Kenichiro
  • 谷 憲三朗 TANI Kenzaburo
  • 山下 勝博 YAMASHITA Katsuhiro
Agents
  • 大野 晃秀 OHNO Koushu
Priority Data
2020-11220129.06.2020JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR MANUFACTURING COMPOSITION INCLUDING ANTIGEN-SPECIFIC ANTIBODY-PRODUCING CELLS, METHOD FOR MANUFACTURING VACCINE COMPOSITION, CELL SEPARATION KIT, AND VACCINE COMPOSITION
(FR) PROCÉDÉ DE FABRICATION D'UNE COMPOSITION COMPRENANT DES CELLULES PRODUCTRICES D'ANTICORPS SPÉCIFIQUES D'UN ANTIGÈNE, PROCÉDÉ DE FABRICATION D'UNE COMPOSITION VACCINALE, KIT DE SÉPARATION DE CELLULES ET COMPOSITION VACCINALE
(JA) 抗原特異的抗体産生細胞を含む組成物の製造方法、ワクチン組成物の製造方法、細胞分離キットおよびワクチン組成物
Abstract
(EN) Provided are a method for manufacturing a composition that includes antigen-specific antibody-producing cells whereby a novel vaccine strategy can be realized, a method for manufacturing a vaccine composition, a cell separation kit, and a vaccine composition. This method for manufacturing a composition that includes antigen-specific antibody-producing cells for producing antigen-specific antibodies includes: a step (1) for bringing acquired peripheral-blood mononuclear cells into contact ex vivo with a cytokine and CD40 ligand together with a soluble antigenic substance; a step (2) for separating specific B cells that are specific to the soluble antigenic substance, and nonspecific B cells that are not specific to the soluble antigenic substance, subsequent to step (1); and a step for culturing the separated specific B cells together with the cytokine and CD40 ligand ex vivo, subsequent to step (2).
(FR) L'invention concerne un procédé de fabrication d'une composition comprenant des cellules productrices d'anticorps spécifiques d'un antigène, permettant de mettre en œuvre une nouvelle stratégie vaccinale, un procédé de fabrication d'une composition vaccinale, un kit de séparation cellulaire et une composition vaccinale. Ce procédé de fabrication d'une composition comprenant des cellules productrices d'anticorps spécifiques d'antigènes pour produire des anticorps spécifiques d'antigènes comprend les étapes suivantes : (1) mise en contact ex vivo de cellules mononucléaires issues du sang périphérique acquis avec une cytokine et un ligand CD40 ainsi qu'une substance antigénique soluble; (2) séparation des lymphocytes B spécifiques à la substance antigénique soluble, et des lymphocytes B non spécifiques à la substance antigénique soluble, après l'étape (1); et (3) culture des lymphocytes B spécifiques séparés avec la cytokine et le ligand CD40 ex vivo, après l'étape (2).
(JA) 新規なワクチン戦略を実現することができる抗原特異的抗体産生細胞を含む組成物の製造方法、ワクチン組成物の製造方法、細胞分離キットおよびワクチン組成物を提供する。 抗原特異的抗体を産生する抗原特異的抗体産生細胞を含む組成物の製造方法は、取得された末梢血単核球をサイトカイン及びCD40リガンドとともに可溶性抗原物質をex vivoで接触させる工程(1)と、工程(1)の後に、可溶性抗原物質に対して特異的な特異的B細胞と、可溶性抗原物質に対して特異的でない非特異的B細胞とを分離する工程(2)と、工程(2)の後に、分離された特異的B細胞をサイトカイン及びCD40リガンドとともにex vivoで培養する工程とを含む。
Latest bibliographic data on file with the International Bureau